Summary of Hualan Biological Engineering (002007.SZ) Earnings Review Company Overview - **Company**: Hualan Biological Engineering - **Ticker**: 002007.SZ - **Industry**: Plasma products and vaccines Key Financial Results - **1H25 Revenue**: Rmb1,798 million, an increase of 9% year-over-year (yoy) [1] - **1H25 Net Profit**: Rmb516 million, an increase of 17% yoy [1] - **Product Revenue Breakdown**: - Albumin: Rmb696 million (+8% yoy) - IVIG: Rmb453 million (-1% yoy) - Other Plasma Products: Rmb588 million (+15% yoy) - Vaccines: Rmb57 million (+93% yoy) [1] Market Dynamics - **Price Decline**: Unit prices for albumin and IVIG declined by approximately 5% [1] - **Competitive Landscape**: Despite price declines, Hualan's performance is considered favorable compared to industry peers, with no inventory pressure reported [1] Regulatory Developments - **Recombinant Albumin Approval**: China's first recombinant albumin was approved on July 18, 2025. However, Hualan management believes the near-term impact on plasma-derived albumin will be minimal due to limited indications [2] - **Long-term Outlook**: Hualan expects human plasma albumin to maintain its usage habits and cost advantages, mitigating concerns about recombinant albumin's threat to the industry [2] Growth Drivers - **Plasma Collection Stations**: Hualan is expanding its raw material supply through the ramp-up of seven nearly-approved plasma collection stations, which are expected to drive growth in plasma products [4] - **Biosimilar Approval**: Hualan Gene, in which Hualan holds a 40% stake, received approval for a bevacizumab biosimilar, generating Rmb58.9 million in revenue for 1H25, although this will not be consolidated into Hualan's financial statements [3] Investment Outlook - **Rating**: The company is rated as a "Buy" with a target price of Rmb19, indicating an upside potential of 8% from the current price of Rmb17.60 [11] - **Valuation Methodology**: The target price is based on a 5-year exit P/E of 18.1x applied to 2025E EPS, referencing a global peer P/E of 19x and a 5-year earnings CAGR of 10% [10] - **Risks**: Key risks include stricter controls on albumin prescriptions, regulatory restrictions affecting IVIG pricing, rising accounts receivable days leading to asset impairments, and intensified competition in the flu vaccine market [10] Revised Estimates - **Revenue Estimates**: Slight revisions made to revenue estimates for 2025E (Rmb4,843 million), 2026E (Rmb5,257 million), and 2027E (Rmb5,589 million), reflecting a decrease of 4.5%, 4.8%, and 5.0% respectively [8] Conclusion - Hualan Biological Engineering is positioned for growth in the plasma products sector, supported by regulatory approvals and expansion of collection capabilities. The company maintains a positive long-term outlook despite competitive pressures and pricing challenges.

Core Viewpoint - Hualan Biological's 2025 mid-year report shows positive growth in revenue and net profit, indicating improved profitability and operational efficiency [1][3]. Financial Performance - Total revenue for the first half of 2025 reached 1.798 billion yuan, an increase of 8.8% year-on-year - Net profit attributable to shareholders was 516 million yuan, up 17.19% year-on-year - In Q2 2025, total revenue was 931 million yuan, a year-on-year increase of 7.53%, with net profit of 203 million yuan, up 13.62% year-on-year [1]. Profitability Metrics - Gross margin improved to 52.58%, an increase of 3.73% year-on-year - Net margin rose to 29.07%, up 7.05% year-on-year - Total selling, administrative, and financial expenses amounted to 278 million yuan, accounting for 15.44% of revenue, a decrease of 8.64% year-on-year [1]. Key Financial Ratios - Earnings per share (EPS) increased to 0.28 yuan, a rise of 17.37% year-on-year - Net asset value per share reached 6.57 yuan, up 6.86% year-on-year - Operating cash flow per share was 0.13 yuan, down 28.21% year-on-year [1]. Business Operations - The company reported a 5.23% increase in plasma collection volume, totaling 803.66 tons in the first half of 2025 - New plasma collection stations were established, contributing to the growth in collection volume [5]. Market Position and Investment Sentiment - The company has a Return on Invested Capital (ROIC) of 7.87%, indicating average capital returns - Analysts expect 2025 performance to reach 1.247 billion yuan, with an average EPS forecast of 0.68 yuan [3]. Fund Holdings - The largest fund holding Hualan Biological is the Harvest CSI Vaccine and Biotechnology ETF, which has reduced its holdings - Other funds have shown varied changes in their positions, with some increasing their stakes [4].

Market Overview - The recombinant protein sector experienced a decline of 1.01%, ranking among the top losers in concept sectors as of the market close on August 28 [1] - Notable declines within the sector included companies such as Aladdin, Bory Pharmaceutical, and Zhongyuan Union, while Chengdu XianDao, Dezhan Health, and Betta Pharmaceuticals saw increases of 7.44%, 2.38%, and 2.02% respectively [1] Concept Sector Performance - The top-performing concept sectors included Copper Cable High-Speed Connection (+5.61%), Co-Packaged Optics (+5.13%), and F5G Concept (+5.12%), while the recombinant protein sector was among the laggards with a decline of 1.01% [2] Capital Flow Analysis - The recombinant protein sector faced a net outflow of 1.348 billion yuan, with 41 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2] - Bory Pharmaceutical led the outflows with a net outflow of 548 million yuan, followed by Zhifei Biological, Hualan Biological, and Zhongyuan Union with net outflows of 149 million yuan, 88.91 million yuan, and 77.72 million yuan respectively [2] Individual Stock Performance - Bory Pharmaceutical reported a decline of 6.63% with a turnover rate of 5.33% and a net outflow of 547.71 million yuan [3] - Chengdu XianDao was the standout performer in the sector, increasing by 7.44% despite a net outflow of 203.74 million yuan [3] - Other notable stocks with significant net inflows included Dezhan Health (+2.38%) with a net inflow of 46.14 million yuan, Haoyuan Pharmaceutical (+1.82%) with a net inflow of 18.75 million yuan, and Maimai Biological (+1.82%) with a net inflow of 18.75 million yuan [4]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company's blood products business is experiencing steady growth, and its gene company is accelerating its development [1] - The company reported a revenue of 1.798 billion yuan in the first half of 2025, representing an 8.8% year-on-year increase, and a net profit attributable to shareholders of 516 million yuan, up 17.19% year-on-year [7] - The company is actively promoting plasma collection, achieving a total collection of 803.66 tons in the first half of 2025, a 5.23% increase compared to the same period last year [7] - The gene company, Hualan Gene, has begun contributing revenue, with sales of Bevacizumab reaching 58.8958 million yuan in the first half of 2025 [7] - The company has adjusted the pricing of its quadrivalent influenza vaccine, which may impact future profit forecasts [7] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 4.867 billion yuan, with a year-on-year growth rate of 11.1% [5] - Net profit attributable to shareholders for 2025 is projected to be 1.203 billion yuan, reflecting a 10.6% year-on-year increase [5] - Earnings per share (EPS) for 2025 is estimated at 0.66 yuan [5] - The company's average industry valuation for 2025 is set at 30X PE, leading to a target market value of 36.1 billion yuan, indicating a 14% upside potential from the current market value [7][8]

Group 1 - Core viewpoint: Hualan Biological (002007.SZ) reported its semi-annual results for 2025, revealing significant institutional investor interest with 29 institutions holding a total of 660 million shares, representing 36.12% of the total share capital [1] - The top ten institutional investors collectively hold 36.05% of Hualan Biological's shares, with a slight decrease of 1.14 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, the Biological Vaccine ETF, increased its holdings, while two funds, including the Innovative Medicine and the China Securities Index Fund, saw a reduction in holdings by 0.26% [2] - A total of 14 new public funds were disclosed this period, including Southern CSI 500 ETF and Ping An CSI A500 ETF, while 9 funds were no longer disclosed, such as E Fund CSI 300 Medical ETF and Huatai-PineBridge CSI 300 ETF [2] - Foreign investment sentiment showed an increase in holdings from one foreign fund, Hong Kong Central Clearing Limited, with an increase of 0.32% [2]

Group 1 - Hualan Vaccine (301207.SZ) reported its semi-annual results for 2025, revealing that as of August 27, 2025, 13 institutional investors held a total of 520 million shares, accounting for 86.46% of the total share capital [1] - The top ten institutional investors include Hualan Biological Engineering Co., Ltd., CYBER CREATOR LIMITED, and several others, with their combined holding ratio increasing by 0.11 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Southern CSI 1000 ETF, increased its holdings, while two funds, including China Merchants National Biomedicine Index A and Tianhong National Biomedicine ETF, reduced their holdings slightly [2] - Four new public funds were disclosed compared to the previous quarter, including Huaxia CSI 1000 ETF and several others [2] - On the foreign investment side, Hong Kong Central Clearing Limited was the only foreign fund to increase its holdings slightly [2]

Group 1 - The company plans to distribute a cash dividend of 6 yuan per 10 shares, totaling approximately 357 million yuan, based on a total of 595,000,033 shares [3][35][40] - The profit distribution plan has been approved by the board and will be submitted for shareholder approval [36][41] - The company reported a net profit of approximately 20.8 million yuan for the first half of 2025, with available profits for distribution amounting to approximately 2.19 billion yuan [38][40] Group 2 - The company has appointed Chen Zhenbo as the new sponsor representative for ongoing supervision, replacing the previous representative due to internal job changes [8][9] - The company will hold its second extraordinary general meeting of 2025 on September 22, 2025, with both on-site and online voting options available for shareholders [11][12][13] Group 3 - The company has effectively managed its fundraising, with approximately 1.31 billion yuan utilized from the total raised amount of approximately 2.28 billion yuan [48][49] - The remaining balance of unused funds is approximately 1.05 billion yuan, with a portion invested in financial products [49][50] - The company has established a special account for managing the raised funds, ensuring compliance with regulatory requirements [50][51]

Investment Rating - The report maintains a "Recommended" rating for Hualan Biological (002007.SZ) [8] Core Views - The blood products segment shows steady growth, with the number of plasma stations and average plasma collection volume leading the industry [5] - The vaccine segment, particularly rabies vaccines, has seen significant revenue growth, while the launch of biosimilars is expected to contribute additional revenue [6] - The company has adjusted its profit forecasts for 2025-2026 and added a new forecast for 2027, estimating net profit attributable to shareholders at 12.45 billion, 14.76 billion, and 16.78 billion respectively [8] Summary by Sections Company Overview - Hualan Biological operates in the pharmaceutical industry, with a total market capitalization of 32.2 billion yuan and a total share capital of 1,827 million shares [1] Financial Performance - In the first half of 2025, the company achieved revenue of 1.798 billion yuan (yoy +8.80%) and a net profit of 516 million yuan (yoy +17.19%) [4] - The blood products segment generated revenue of 1.737 billion yuan (yoy +7.57%), with a gross margin of 51.69% [5] Future Projections - Revenue projections for 2024A, 2025E, 2026E, and 2027E are 4.379 billion, 4.945 billion, 5.529 billion, and 6.095 billion respectively, with corresponding net profit estimates of 1.088 billion, 1.245 billion, 1.476 billion, and 1.678 billion [7][9] - The company anticipates a gradual increase in gross margin from 61.4% in 2024 to 62.1% in 2027 [10] Investment Considerations - The report highlights the potential for accelerated growth due to the upcoming launches of biosimilars by the subsidiary Hualan Gene [8]

Core Points - On August 27, the company Hualan Biological announced a semi-annual distribution plan for 2025, proposing a cash dividend of 5 yuan per 10 shares (including tax), with a total expected payout of 914 million yuan, representing 177.13% of net profit and a dividend yield of 3.08% based on the average trading price for the period [2][3][5] Financial Performance - For the first half of 2025, the company reported operating revenue of 1.798 billion yuan, an increase of 8.80% year-on-year, and a net profit of 516 million yuan, up 17.19% year-on-year, with basic earnings per share of 0.2824 yuan and a weighted average return on equity of 4.3% [3][4] Market Activity - On August 27, the stock experienced a net inflow of 58.25 million yuan from major funds, with a total net inflow of 169 million yuan over the past five days [4] - The latest margin financing balance for the stock is 1.456 billion yuan, with an increase of 51.46 million yuan over the past five days, reflecting a growth rate of 3.66% [5] Industry Comparison - Among the 53 companies in the pharmaceutical and biotechnology sector that announced semi-annual distribution plans for 2025, Hualan Biological ranks second in total cash payout, following WuXi AppTec, which announced a payout of 1.003 billion yuan [5]

Core Viewpoint - Hualan Biological's half-year report for 2025 shows strong performance driven by its "blood products + vaccines + recombinant protein drugs" strategy, with significant revenue and profit growth [1][2][3] Financial Performance - The company achieved a revenue of 1.798 billion yuan, an increase of 8.8% year-on-year, and a net profit of 515 million yuan, up 17.19% year-on-year [1] - The blood products segment generated 1.738 billion yuan, reflecting a growth of 7.49% year-on-year, with a net profit of 502 million yuan, an increase of 18.51% year-on-year [1] Dividend Policy - Hualan Biological plans to distribute a dividend of 5 yuan per 10 shares (including tax), totaling 913 million yuan, and aims to enhance the stability and predictability of cash dividends in the future [1] Market Position and Growth Drivers - As a leading player in the domestic blood products industry, Hualan Biological's market share and comprehensive utilization rate remain strong, showcasing resilience and high-quality development [2] - The company collected 803.66 tons of plasma in the first half of the year, a 5.23% increase year-on-year, indicating ongoing growth in plasma collection [2] Research and Development - Hualan Biological invested 161.35 million yuan in R&D, accounting for 8.97% of revenue, and is advancing its pipeline with 9 major projects in clinical trials or application stages [2] - The company is actively developing innovative drugs in various therapeutic areas, including stem cells and cardiovascular diseases, which are expected to create new profit growth points [2] Strategic Outlook - The effectiveness of the "blood products + vaccines + recombinant protein drugs" strategy is validated by the strong half-year performance, indicating robust core business vitality [3] - With the anticipated recovery in domestic vaccine demand and increasing concentration in the blood products industry, Hualan Biological is positioned to expand its market share further [3]